Hematology

Latest News

Comparative Analysis Suggests Zanubrutinib as Most Effective cBTKi in R/R CLL

July 5th 2025

The indirect comparative analysis is the first of its kind to assess the relative efficacy of approved covalent Bruton tyrosine kinase inhibitors (cBTKis) in the absence of head-to-head trials.

White blood cells | Image credit: Sebastian Kaulitzki - stock.adobe.com
Basophil, Eosinophil Counts Could Be Prognostic Indicators in ET, PV

July 2nd 2025

FDA approved | Image credit: DG-Studio – stock.adobe.com
FDA Approves Linvoseltamab to Treat R/R Multiple Myeloma

July 2nd 2025

Multiple myeloma words appearing on table | Image credit: ibreakstock - stock.adobe.com
Lower Tregs Linked With Survival in Multiple Myeloma

July 1st 2025

FDA headquarters | Image Credit: Tada Images - stock.adobe.com
FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS

June 30th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

Smoldering Multiple Myeloma Research Promising but Not Yet Translatable to Change in Care
June 2nd 2020

Smoldering Multiple Myeloma Research Promising but Not Yet Translatable to Change in Care

Jared Kaltwasser
As investigators have learned more about how to diagnose and categorize smoldering multiple myeloma (SMM), a new review article argues there’s insufficient data to evolve beyond a close observation approach.
Multiple Myeloma With CNS Relapse a Challenging Puzzle for Clinicians
May 30th 2020

Multiple Myeloma With CNS Relapse a Challenging Puzzle for Clinicians

Jared Kaltwasser
A new review article outlining research into multiple myeloma with central nervous system (CNS) involvement explains the many reasons it is difficult to diagnose and treat the disease.
Patient Perception of Sickle Cell Care Differs by Acute vs Nonacute Settings
May 29th 2020

Patient Perception of Sickle Cell Care Differs by Acute vs Nonacute Settings

Allison Inserro
Helping patients find a clinician who is experienced with sickle cell disease can have many positive benefits, a new study noted.
Minimal Residual Disease Status Appears to Correlate With Patient-Centered Outcomes in Those With Hematological Malignancies
May 29th 2020

Minimal Residual Disease Status Appears to Correlate With Patient-Centered Outcomes in Those With Hematological Malignancies

Jared Kaltwasser
Clinicians use the presence or absence of minimal residual disease as a metric by which to judge the efficacy of therapy in patients with hematological malignancies. A new review article interrogates whether that approach aligns with patient-centered outcomes.
Long-term Survival Increasing in Patients With Hematologic Malignancies
May 29th 2020

Long-term Survival Increasing in Patients With Hematologic Malignancies

Jared Kaltwasser
New advances in therapy have led to better long-term survival rates in patients with hematologic malignancies, but there are some caveats to the good news.
AML, Multiple Myeloma Can Be Treated Simultaneously, According to Case Study
May 16th 2020

AML, Multiple Myeloma Can Be Treated Simultaneously, According to Case Study

Jared Kaltwasser
It’s rare for a patient to be diagnosed with both acute myeloid leukemia and multiple myeloma at the same time, but a new case study suggests there are options to treat both diseases at the same time in such cases.
Chronic Transfusion Therapy for Sickle Cell Burdens Patients, Families, Study Says
May 15th 2020

Chronic Transfusion Therapy for Sickle Cell Burdens Patients, Families, Study Says

Jared Kaltwasser
A new study based on interviews with families and patients undergoing chronic transfusion therapy for sickle cell disease finds that the therapy affects the families in ways that extend beyond health.
Whites With Multiple Myeloma, Vitamin D Deficiency Have Lower Survival Rates
May 10th 2020

Whites With Multiple Myeloma, Vitamin D Deficiency Have Lower Survival Rates

Jared Kaltwasser
New data suggests white patients who are deficient in vitamin D have lower rates of survival when diagnosed with multiple myeloma. The phenomenon was not seen, however, in African American patients.
What Are the Health Care Access and Quality Factors in Multiple Myeloma Survival?
May 5th 2020

What Are the Health Care Access and Quality Factors in Multiple Myeloma Survival?

Jared Kaltwasser
New research suggests disparities in incidence and survival rates in multiple myeloma may have a lot to do with healthcare quality and access to care.
Extramedullary Disease in MM Tough to Treat, Even With Newer Therapies, Study Says
April 30th 2020

Extramedullary Disease in MM Tough to Treat, Even With Newer Therapies, Study Says

AJMC Staff
Outcomes were worse for patients with multiple myeloma (MM) and extramedullary disease, and the authors said their findings indicate that evaluation of extramedullary response using imaging is needed in this group.
COVID-19 Increases Overall Risk of Death, Complications in Patients With Cancer, Study Shows
April 29th 2020

COVID-19 Increases Overall Risk of Death, Complications in Patients With Cancer, Study Shows

Maggie L. Shaw
Recent study results show that patients with cancer who develop coronavirus disease 2019 (COVID-19) are far more likely to die than those who develop COVID-10 but do not have cancer. Patients being treated with immunotherapy appear to be at particularly high risk.
Report Describes Patient With MM, COVID-19 Treated Successfully With Tocilizumab
April 25th 2020

Report Describes Patient With MM, COVID-19 Treated Successfully With Tocilizumab

Jared Kaltwasser
A new article outlining the experience of a patient with a history of multiple myeloma (MM) who contracted coronavirus disease 2019 (COVID-19) shows the interleukin-6 receptor inhibitor tocilizumab was an effective therapy.
What Is the Economic Value of Receiving CAR T-Cell Therapy in an Outpatient Setting?
April 25th 2020

What Is the Economic Value of Receiving CAR T-Cell Therapy in an Outpatient Setting?

Gianna Melillo
Chimeric antigen receptor (CAR) T-cell therapy has been shown to improve health-related quality of life in patients with relapsed/refractory diffuse large B-cell lymphoma (LBCL). Currently, CAR T-cell therapies are primarily administered in inpatient settings. In a study published in JAMA Network Open, researchers found CAR T-cell therapy administered to patients with relapsed or refractory LBCL in outpatient settings was associated with lower estimated overall costs.
What We're Reading: Public Fears Worst of Pandemic; Blood Clotting and COVID-19; VA Facilities Struggle
April 23rd 2020

What We're Reading: Public Fears Worst of Pandemic; Blood Clotting and COVID-19; VA Facilities Struggle

AJMC Staff
A new poll conducted by the Kaiser Family Foundation shows a majority of Americans fear the worst of the coronavirus disease 2019 (COVID-19) pandemic is yet to come; reports of blood clots in patients with COVID-19 raise concerns; Veterans' Affairs medical facilities are struggling to cope with the pandemic.
Dr Elisabet Manasanch: Identifying Patients With Smoldering Multiple Myeloma Remains an Unmet Need
April 16th 2020

Dr Elisabet Manasanch: Identifying Patients With Smoldering Multiple Myeloma Remains an Unmet Need

Identifying patients with smoldering multiple myeloma is difficult as they often do not have any symptoms, but we could still do a much better job than what we are currently implementing, said Elisabet Manasanch, MD, assistant professor in the Department of Lymphoma/Myeloma and Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Mitochondrial Pathways Not the Culprit in Bortezomib Neurotoxicity, Study Finds
April 15th 2020

Mitochondrial Pathways Not the Culprit in Bortezomib Neurotoxicity, Study Finds

Jared Kaltwasser
New research evaluates bortezomib and carfilzomib in an attempt to understand the causes of neurotoxicity in the former. They found the mitochondrial pathway is likely not the problem.
FDA's Revised Blood Donation Guidance for Gay Men Still Courts Controversy
April 4th 2020

FDA's Revised Blood Donation Guidance for Gay Men Still Courts Controversy

Maggie L. Shaw
The FDA has announced a relaxing of its restrictions on gay men being allowed to donate blood, in light of the coronavirus disease 2019 pandemic. Instead of 1 year, if a male has had sex with another male, he need only wait 3 months to donate blood.
Carfilzomib Improves Prognosis in Patients With High-Risk Multiple Myeloma, Study Finds
March 29th 2020

Carfilzomib Improves Prognosis in Patients With High-Risk Multiple Myeloma, Study Finds

Jared Kaltwasser
Patients with high-risk multiple myeloma tend to have significantly worse prognoses compared to those in the standard-risk category. A new study offers a potential solution.
Site Logo
March 23rd 2020

Why Donate Blood During the Coronavirus Crisis? Because I Can

Maggie L. Shaw
I am type O negative. There are only 7% of us in the United States. My blood is red gold, if you will. I am a universal donor, which means that my blood can go to anyone.
Study Examines Fixed-Duration Therapy in Patients With MM Ineligible for Transplants
March 22nd 2020

Study Examines Fixed-Duration Therapy in Patients With MM Ineligible for Transplants

Jared Kaltwasser
Newly diagnosed patients with multiple myeloma (MM) who are transplant-ineligible sometimes plan fixed-duration therapy to improve their quality of life. A new study examines the impact of that approach.
COVID-19 and Cancer: Practices Seek to Protect Patients, Providers From Growing Pandemic
March 21st 2020

COVID-19 and Cancer: Practices Seek to Protect Patients, Providers From Growing Pandemic

Allison Inserro
Some patients with cancer are more vulnerable than others, said Jeffrey Patton, MD, acting chief executive officer and president of physician services of OneOncology, as well as chief executive office of Tennessee Oncology, which is down to its last 14-day supply of personal protective equipment.
Hydroxycarbamide Therapy Shown to Improve Memory, IQ of Adolescents With Sickle Cell Disease
March 17th 2020

Hydroxycarbamide Therapy Shown to Improve Memory, IQ of Adolescents With Sickle Cell Disease

Matthew Gavidia
In adolescent patients with sickle cell disease, hydroxycarbamide therapy was associated with improvements in neurocognition variables such as working memory, verbal memory, and nonverbal IQ, according to study findings.
Dr Elisabet Manasanch Discusses Current Standards of Treatment for Smoldering Multiple Myeloma
March 16th 2020

Dr Elisabet Manasanch Discusses Current Standards of Treatment for Smoldering Multiple Myeloma

There are studies exhibiting progression within treatment for smoldering multiple myeloma, but nothing has been FDA approved yet, said Elisabet Manasanch, MD, assistant professor in the Department of Lymphoma/Myeloma and Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Dr C. Patrick Carroll Discusses Treating Patients With SCD-Related Pain Who Arrive in the ED
March 12th 2020

Dr C. Patrick Carroll Discusses Treating Patients With SCD-Related Pain Who Arrive in the ED

When patients present to the emergency department (ED) with sickle cell disease (SCD)–related pain, they often have been experiencing that pain for days, said C. Patrick Carroll, MD, director of psychiatric services, Sickle Cell Center for Adults, associate professor of psychiatry, Johns Hopkins Medicine.
Vitamin D Deficiency Associated With Worse Hospital Outcomes in Pediatric Patients With Sickle Cell Disease
March 11th 2020

Vitamin D Deficiency Associated With Worse Hospital Outcomes in Pediatric Patients With Sickle Cell Disease

Matthew Gavidia
In children and adolescents with sickle cell disease, those who lacked ample vitamin D were hospitalized more often, had longer hospital stays, and made more frequent visits to the emergency department, according to study findings.
What We're Reading: Second Person Cured of HIV Speaks Out; BMS' MM Therapy Fails Study; FDA to Review Biosimilar Bevacizumab
March 9th 2020

What We're Reading: Second Person Cured of HIV Speaks Out; BMS' MM Therapy Fails Study; FDA to Review Biosimilar Bevacizumab

AJMC Staff
A year after being only the second person to be cured of HIV, the “London Patient” revealed his identity; BMS announced today that its combination therapy for multiple myeloma—elotuzumab, lenalidomide, and dexamethasone—failed its primary endpoint of progression-free survival in its phase 3 ELOQUENT-1 trial; Biocon and Mylan N.V. announced that the FDA accepted their biologics license application (BLA) for MYL-14020, a proposed biosimilar to bevacizumab (Avastin), for review.
FDA Approves Isatuximab-irfc for Treatment of Relapsed Refractory Multiple Myeloma
March 5th 2020

FDA Approves Isatuximab-irfc for Treatment of Relapsed Refractory Multiple Myeloma

Matthew Gavidia
Isatuximab-irfc, sold as Sarclisa, in combination with pomalidomide and dexamethasone, was approved this week by the FDA for the treatment of adults with relapsed refractory multiple myeloma who have received at least 2 prior therapies.
Dr Adam Olszewski on Research Still Needed on Palliative Care Services in Blood Cancers
March 3rd 2020

Dr Adam Olszewski on Research Still Needed on Palliative Care Services in Blood Cancers

More data is needed to get wider acceptance of the use of palliative care services for patients with blood cancers, said Adam Olszewski, MD, associate professor of medicine at The Warren Alpert Medical School of Brown University.
Higher Microbiota Diversity in Hematologic Cancer Treatment Could Lower Mortality Risk, Study Finds
February 27th 2020

Higher Microbiota Diversity in Hematologic Cancer Treatment Could Lower Mortality Risk, Study Finds

Matthew Gavidia
For patients undergoing allogeneic hematopoietic cell transplantation, higher diversity of intestinal microbiota at the time of neutrophil engraftment was linked with lower mortality, according to study findings published today.
Multiple Myeloma Rates in China Align With Other Asian Countries
February 23rd 2020

Multiple Myeloma Rates in China Align With Other Asian Countries

Jared Kaltwasser
In a major study of a Chinese medical insurance database, investigators found the prevalence and incidence of the disease in China is similar to those of its neighbors, but lower than countries in the West.
<1
...
789101112131415
...
27>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo